1 Title

- 2 A study to assess the impact of cobas Liat point-of-care PCR assays (SARS-CoV-2 and
- 3 Influenza A/B) on patient clinical management in the emergency department of the
- 4 University of California at Davis Medical Center

5 Authors

6 Larissa May,¹ Elissa M. Robbins,² Jesse A. Canchola,² Kamal Chugh,² Nam K. Tran³

7 Affiliations

- 8 ¹Department of Pathology and Laboratory Medicine, University of California, Davis,
- 9 Sacramento, California, USA
- 10 ²Roche Molecular Systems, Pleasanton, California, USA
- ³Department of Emergency Medicine, University of California, Davis, Sacramento, California,
 USA

13 Corresponding author

- 14 Nam K. Tran
- 15 University of California, Davis,
- 16 CA 95616, USA
- 17 Tel: 530-752-7355
- 18 E-Mail: <u>nktran@UCDAVIS.EDU</u>

19 Running head

20 Use of cobas Liat SARS-CoV-2 and Influenza A/B assays

21 Author contributions

- 22 NKT, EMR, and LM were involved in the conception and design of the work, data collection,
- 23 and data interpretation. JAC and KC were involved in data analysis and interpretation. All

- 24 authors contributed to the drafting and critical revision of the article and gave their final
- approval of the manuscript to be published.

27 Abstract

28 Background

- 29 Rapid detection of SARS-CoV-2 is crucial for reduction of transmission and clinical decision-
- 30 making. The cobas[®] SARS-CoV-2 & Influenza A/B nucleic acid test for use on the cobas
- 31 Liat[®] System is a rapid (20 minutes) point-of-care (POC) polymerase chain reaction (PCR)
- 32 method.

33 Methods

- 34 This unblinded, pre-post study enrolled consecutive patients with symptoms/signs consistent
- 35 with SARS-CoV-2 infection presenting to the University of California, Davis emergency

36 department (ED). Outcomes following implementation of the cobas Liat SARS-CoV-2 &

37 Influenza A/B test (intervention period: December 2020–May 2021) were compared with

- 38 previous standard-of-care using centralized laboratory PCR methods (control period: April
- 39 2020–October 2020).

40 Results

41 Electronic health records of 8879 symptomatic patients were analyzed, comprising 4339 and 42 4540 patient visits and 538 and 638 positive SARS-CoV-2 PCR test results in the control 43 and intervention periods, respectively. Compared with the control period, turnaround time 44 (TAT) was shorter in the intervention period (median 0.98 vs 12.3 hours: p<0.0001). ED 45 length of stay (LOS) was generally longer in the intervention period compared with the 46 control period, but for those SARS-CoV-2-negative who were admitted, ED LOS was shorter 47 (median 12.53 vs 17.93 hours; p<0.0001). Overall, the rate of anti-infective prescribing was 48 also lower in the intervention period than in the control period (antibiotics only: 38.11% vs 49 44.55%; p<0.0001 and antivirals only: 3.13% vs 0.94%; p<0.0001).

50 Conclusion

- 51 This real-world study confirms faster TAT with a POC PCR method in an emergency care
- 52 setting and highlights the importance of rapid SARS-CoV-2 detection to aid patient
- 53 management and inform treatment decisions.

54 Clinical Relevance

- 55 This study reports data collected from a quasi-experimental pre-post study using the
- 56 electronic health records of patients presenting to the emergency department (ED) of the
- 57 University of California at Davis Medical Center with symptoms or signs consistent with
- 58 SARS-CoV-2 infection during their ED visit. The primary objective of this study was to
- 59 determine if implementation of the point-of-care (POC) cobas[®] Liat[®] SARS-CoV-2 &
- 60 Influenza A/B test for use on the cobas Liat System reduced the diagnostic turnaround time
- and/or length of stay for ED patients with suspected SARS-CoV-2 infection compared with
- 62 the previous standards of care (batch-wise diagnostic testing using the cobas 6800 System
- and on-demand urgent testing on the GenMark Dx[®] ePlex[®] system in a centralized clinical
- 64 laboratory). Ultimately, these data help to inform how implementation of POC molecular
- 65 testing methods impact patient management.
- 66

67 Keywords

68 SARS-CoV-2; molecular testing; PCR; point-of-care; diagnosis

69 Introduction

70	As of May 26, 2022, the coronavirus disease (COVID-19) pandemic has resulted in an
71	estimated 83,408,645 cases of COVID-19 in the United States (US), and 1,000,254 deaths
72	(1). Even as vaccination levels increase in the general population, testing of symptomatic
73	individuals is vital for controlling the spread of SARS-CoV-2 (severe acute respiratory
74	syndrome coronavirus 2; the causative agent of COVID-19), as vaccination alone does not
75	prevent infection and transmission (2, 3). The choice of diagnostic test (e.g., nucleic acid
76	amplification test [NAAT] or antigen detection and point-of-care [POC] or centralized testing)
77	is setting dependent (4). Resources (e.g., availability of trained staff), turnaround time (TAT),
78	testing capacity, assay performance (sensitivity and specificity), and patient characteristics,
79	such as days since symptom onset, all need to be considered (4).
80	Vaccination has resulted in the relaxation of public health mitigation measures in many
81	geographical regions (5-7). The increase in respiratory viruses that had hitherto been
82	reduced due to physical distancing measures (8, 9) makes it important for a clinician to
83	determine whether COVID-19-associated symptoms are attributable to SARS-CoV-2
84	infection, another respiratory infection (4), or a non-infectious etiology. The SARS-CoV-2
85	Omicron (B.1.1.529) variant, which has a shorter incubation period than the Alpha (B.1.1.7)
86	variant (10) and potentially higher transmissibility than the ancestral viruses (11), increases
87	the need for rapid diagnosis. As the pandemic has evolved, monoclonal antibody therapies
88	have become available that are more effective if administered in the early stages of
89	symptomatic infection (12), meaning that rapid diagnosis also has important implications for
90	treatment.

In the emergency department (ED), test results are often not immediately available (13);
typical TATs for high-throughput NAATs can range from ~1.5 hours to 8 hours (14), with
approximately 97% of polymerase chain reaction (PCR) results available within 23 hours

94 from arrival in the ED (13). Symptomatic patients should be isolated in an examination room 95 or designated area, in the absence of a laboratory-confirmed diagnosis, with consequences 96 for allocations of hospital resources, including the need for isolation bays and personal 97 protective equipment (15, 16). Given the implications for infection prevention, and the 98 variability in isolation capacity (16), rapid results are helpful for the effective triage of ED 99 patients with suspected SARS-CoV-2, both to reduce transmission and to identify those that 100 may benefit from hospital admission or other therapeutic intervention (4). Further, performing 101 on-demand POC testing in the ED while using centralized high-throughput systems for less 102 urgent testing needs could increase overall testing capacity. 103 At the onset of this study, the University of California (UC) at Davis Medical Center 104 performed diagnostic testing in a centralized clinical laboratory. The cobas[®] Liat[®] SARS-105 CoV-2 & Influenza A/B nucleic acid test for use on the cobas Liat System (cobas Liat SARS-106 CoV-2 & Influenza A/B test) is intended for the simultaneous rapid in vitro detection and 107 differentiation of SARS-CoV-2 and influenza A and B virus nucleic acids in clinical 108 specimens from individuals suspected of respiratory viral infection (17). The assay provides 109 results from a single test to rule-in or rule-out influenza and COVID-19 simultaneously, within 110 approximately 20 minutes (17). 111 The primary objective of this study was to determine if implementation of the cobas Liat 112 SARS-CoV-2 & Influenza A/B test reduced the diagnostic assay TAT and/or length of stay 113 (LOS) for ED patients with suspected SARS-CoV-2 infection compared with the previous 114 standards of care. The secondary objectives were to determine the impact of POC testing on

115 ED disposition and the use of anti-infectives in patient management.

116 Materials and Methods

117 Study design

118 This was a retrospective, unblinded, quasi-experimental pre-post study The study comprised 119 two periods: a control period (April 01, 2020 to October 31, 2020) and an intervention period 120 (December 01, 2020 to May 31, 2021).

121 Participants

- 122 Individuals presenting at the UC Davis ED were included in the study consecutively if they
- had symptoms or signs consistent with COVID-19 at their ED visit (Supplementary Table
- 124 S1). A real-time reverse transcriptase PCR (RT-PCR) SARS-CoV-2 test must also have
- been ordered by the ED physician during the patient's ED visit, in either study period. For
- 126 each patient included in the study, the information of a complete event, defined as all
- 127 diagnostics and prescriptions ordered within 30 days of the initial ED visit, was collected
- 128 using electronic health records.

129 Sample collection, storage and testing

130 Samples were collected according to manufacturer instructions and analyzed as soon as 131 possible, not exceeding maximum storage times and temperatures dictated by the 132 manufacturer's instructions for use (IFU) (17-19). In the control period, centralized diagnostic 133 testing was conducted using the cobas SARS-CoV-2 test on the cobas 6800 System (19) or 134 on-demand urgent testing using the GenMark Dx[®] ePlex[®] SARS-CoV-2 Test (18). The cobas 135 6800 System can perform more than 1000 tests per day, with first results reported in 136 approximately 3 hours of loading (20, 21). In contrast, the assay run time for the ePlex 137 SARS-CoV-2 Test is approximately 90 minutes (22) allowing for up to 288 samples per day 138 (23) depending on instrument configuration and lab staffing. In the intervention period, the 139 cobas Liat SARS-CoV-2 & Influenza A/B test was used for detection of the target sequences 140 (17).

141 Analysis

For the purpose of this analysis, data from the two centralized testing methods were pooled to allow the comparison between POC PCR and centralized PCR methods. Data collected during November 2020 were excluded from the analysis as this was considered a transition period, allowing a phasing in of the POC assay. Samples yielding indeterminate/invalid results were handled per the assay IFUs (17-19).

- 147 More information on test methods and analysis is available in the Supplementary
- 148 Materials.
- 149 Statistical analysis

150 No formal sample size calculations were conducted for this study. All data analyses were

151 performed using SAS/STAT[®] v9.4 software (24). Comparisons were made at the patient

152 visit-level rather than continuously over the study duration. Patient data included in this study

153 were summarized using descriptive statistics and compared between the control and

154 intervention periods. The primary endpoints of TAT and LOS, and the secondary endpoints

155 of ED disposition and anti-infective prescription rates, were also analyzed by SARS-CoV-2

156 test result. A post hoc analysis of LOS and anti-infective use was conducted to stratify data

157 by ED disposition and by SARS-CoV-2 test result and ED disposition.

158 Statistical hypothesis testing was performed using the Chi-Square test for categorical data,

159 the non-parametric Wilcoxon rank-sum test for continuous-level non-normally distributed

data and the Student's t-test for normally distributed data. The rate of type I errors was

161 controlled for using the false discovery rate method when conducting multiple comparisons.

162 Indeterminate/invalid results were combined and included in the relevant tables but were not

included in statistical hypothesis testing due to small sample sizes.

164 *Ethics statement*

- 165 This study was conducted in compliance with the International Conference on Harmonisation
- 166 Good Clinical Practice Guidelines, and applicable US Food and Drug Administration
- 167 regulations. The study protocol and de-identification procedure for patient data were
- 168 approved by the UC Davis Institutional Review Board Administration.
- 169 Data availability
- 170 The data used to support the findings of this study are included within the article and
- 171 supplementary materials.

172 Results

- 173 Patient demographics and characteristics
- 174 A total of 8879 medical records were included in the study (Supplementary Error!
- 175 Reference source not found.). Patient demographics were similar (all comparisons, p>0.05)
- in the control and intervention cohorts (Table 1) and were therefore not controlled for in
- 177 subsequent analyses. Across both periods, mean patient age was 47 years (median 51
- 178 years), the majority were White (42.03%), and 48.64% were female. Almost 40% of patients
- had a body mass index below the cut-off for obesity ($<30.0 \text{ kg/m}^2$) (25).
- 180 The most commonly recorded SARS-CoV-2-related symptom was shortness of
- 181 breath/difficulty breathing (21.83% control period, 18.57% intervention period)
- 182 (Supplementary Table S1). Only one symptom was recorded for 54.51% of patients in
- 183 control period and 47.97% in the intervention period), with 2 or ≥3 symptoms reported by
- 184 <3% of patients each in either period (**Supplementary Table S2**).
- 185 More SARS-CoV-2 PCR tests were conducted in the intervention period than in the control
- 186 period (n=4540 vs n=4339), and of those, more tested positive in the intervention period
- 187 (14.05% vs 12.40%, respectively). Twelve (0.28%) tests were recorded as invalid/other in

the control period versus none in the intervention period (**Supplementary Table S3**; p<0.02

- 189 overall for test outcome between periods).
- 190 Impact of rapid POC testing on TAT
- 191 The TAT (defined here as time from electronic SARS-CoV-2 test order to result reporting)
- 192 was shorter in the intervention period compared with the control period (median 0.98 vs 12.3
- hours; p<0.0001) (Table 2). The lower end of the range for TAT in the control period (range
- 194 1.92, 74.38 hours) likely reflects samples analyzed with the ePlex SARS-CoV-2 Test, which

195 has a shorter TAT than the cobas 6800. TAT was similarly reduced in the intervention period

- 196 when analyzed by SARS-CoV-2 test result (**Table 2**) and when TAT was calculated as the
- time from sample collection to result reporting (Supplementary Table S4).
- 198 Impact of rapid POC testing on ED LOS
- 199 Median ED LOS was longer in the intervention period (7.56 vs 7.15 hours; p=0.02) and for
- 200 patients positive for SARS-CoV-2 (p<0.0001) (**Table 3**). ED LOS was similar in both periods
- 201 for patients negative for SARS-CoV-2. By ED disposition, median LOS was longer in the
- intervention period for those who were discharged after ED care (5.10 hours vs 4.43 hours;
- 203 p<0.0001) but shorter for those admitted (13.50 hours vs 18.48 hours; p<0.0001). ED LOS
- 204 was similar in both periods for those who were admitted to the intensive care unit (ICU) or
- 205 who died (both p>0.05) (**Table 3**).
- 206 By SARS-CoV-2 test result and ED disposition, median ED LOS was longer in the
- 207 intervention period for those who were discharged, regardless of test result (both p<0.0001)
- 208 (Supplementary Table S5). For those admitted, median ED LOS was longer in the
- 209 intervention period for patients with a positive SARS-CoV-2 result (p=0.02) and shorter with
- a negative result (p<0.0001).

211 Hospital LOS was similar between study periods overall and when analyzed by SARS-CoV-2

- result (all comparisons, p>0.05; **Supplementary Table S6**). ICU LOS was shorter in the
- intervention period compared with the control period overall (2.08 days vs 2.49 days;
- p=0.01) and for those with a negative SARS-CoV-2 result (p=0.01) (Supplementary Table
- 215 **S7**). Patients with a positive SARS-CoV-2 result had a similar ICU LOS in both periods
- 216 (p>0.05).
- 217 Impact of rapid POC testing on ED disposition
- 218 Fewer patients were admitted to the ICU in the intervention period (11.78%) compared with
- the control period (14.22%; p=0.0026) (Table 4). Patients with a positive SARS-CoV-2 result
- in the intervention period were more likely to be admitted to the hospital (p=0.0002) and less
- 221 likely to be discharged (p=0.0002). Conversely, patients who tested negative were less likely
- to be admitted to the ICU in the intervention period (p=0.0006).
- 223 Impact of rapid POC testing on antibiotic/antiviral use
- Antibiotic-only use was 14.5% lower in the intervention period (38.11% vs 44.55%;
- p<0.0001; **Table 5**), and the magnitude of the change was greater in patients with a positive
- vs negative SARS-CoV-2 result (47.2% vs 10.6% reduction; p<0.0001 for both). Antiviral-
- 227 only use was higher in the intervention period compared with the control period (3.13% vs
- 228 0.94%; p<0.0001). Antivirals were prescribed more in the intervention period when patients
- 229 were SARS-CoV-2 positive (14.89%) than when negative (0.92%). Approximately half of
- 230 patients received no antibiotic or antiviral in both periods, though a higher proportion of
- patients received neither in the intervention period (54.25% vs 49.97%; p<0.0001).
- 232 Patterns of anti-infective prescription were similar when analyzed by ED disposition (Table
- 233 5). However, as would be expected based on prescribing requirements, greater prescription
- of antivirals in the intervention period compared with the control period was more evident in
- those admitted to hospital or the ICU. By SARS-CoV-2 test result and ED disposition

(Supplementary Table S8), antibiotic-only use in the intervention period compared with the
control period was considerably lower in positive patients who were discharged or admitted
(both p<0.0001). For SARS-CoV-2-negative patients, antibiotic prescriptions were similar in
both periods for those who were discharged (p>0.05) but lower in the intervention period for
those who were admitted to hospital (p=0.01).

241 Summaries of antibiotic and antiviral prescription rates by month are available in

242 Supplementary Tables S9 and S10, respectively.

243 Discussion

244 In this large study, ED patients with signs or symptoms consistent with COVID-19 received 245 POC PCR test results in under an hour, compared with approximately 12 hours for 246 centralized tests, when averaged across the cobas SARS-CoV-2 test and ePlex Test. The 247 faster TAT did not reduce median ED LOS overall but did appear to reduce ED LOS for 248 patients with negative test results who were subsequently admitted, suggesting more 249 effective patient triage. The rate of antibiotic prescribing was also lower in the intervention 250 period than in the control period overall, and in the population of patients with a positive 251 SARS-CoV-2 result, which could support improved antibiotic stewardship with faster 252 diagnosis.

Previous studies have evaluated the clinical performance of the cobas Liat SARS-CoV-2 & Influenza A/B test compared with other RT-PCR systems, such as the Cepheid[®] GeneXpert system[®] (26) and the cobas SARS-CoV-2 test on the cobas 6800/8800 Systems (27), and have demonstrated 100% positive percent agreement and 97–100% negative percent agreement. One study, conducted in an ED in Germany, estimated that POC PCR results using the cobas Liat System were available after 102 minutes from admission, which was shorter than the 811 minutes with central laboratory PCR (28). Though the TAT observed in

260 the clinic is longer than the 20-minute assay run time, demonstrating some delay in the 261 testing strategy, time to result is still substantially shorter than for centralized PCR methods. 262 Fast TAT with a reliable POC PCR assay for respiratory pathogens can reduce ED LOS 263 (29). However, as in our study, some have reported increased ED LOS following the 264 introduction of rapid diagnostic tests (30, 31). It is likely that factors other than TAT, such as 265 availability of hospital resources (including number of isolation rooms), severity of symptoms, 266 and presence of comorbidities requiring further work-up, contribute to longer ED LOS (30, 267 31). In this study, the ED had a higher number of symptomatic patient visits and positive 268 SARS-CoV-2 test results in the intervention period than in the control period, likely related to 269 the emergence of several SARS-CoV-2 variants, most notably Delta, diving surges (32), 270 which may have contributed to increased LOS in the intervention period. Despite this, we 271 found that ED LOS for patients with negative test results who were admitted was shorter 272 following POC PCR implementation, indicating more effective patient triage. 273 Across both study periods, approximately 50% of ED patients were discharged and 37% 274 were admitted. Though ICU admissions were lower in the intervention period, this result 275 should be interpreted with care. Lower ICU admissions could indicate improved patient 276 triage and management, which would have cost-saving implications (33, 34), but it is 277 possible that patients in the control period had a variant associated with more severe 278 disease (35), or that the reduction was due to other changes in hospital practices. Admission 279 rates appeared higher than in other studies of symptomatic patients who were PCR tested 280 for SARS-CoV-2, where admission rates were approximately 27–28% (36, 37). Higher 281 admission rates could reflect the severity of symptoms encountered in this cohort, 282 differences in hospital practices, or factors such as comorbidities that have not been

283 controlled for. The UC Davis Medical Center is also a quaternary referral center, and the ED

serves as a safety net for vulnerable populations and those with comorbidities of concern.

285 Several studies have demonstrated that implementing rapid POC PCR tests can improve 286 clinical decision-making and management of patients with respiratory infections (27, 38, 39). 287 Shorter time to diagnosis can reduce inappropriate antibiotic prescribing and allow for 288 appropriate de-escalation (29, 38-41). Within the first 6 months of the pandemic, antibiotic 289 prescribing rates for patients with COVID-19 was high (almost 75%), even in the absence of 290 bacterial co-infection (42). In our study, though antibiotics were frequently prescribed, the 291 rate was lower in the intervention period than in the control period, particularly in those with a 292 positive SARS-CoV-2 result, supporting the notion that reduced time to result can improve 293 antibiotic stewardship and help slow the emergence of antibiotic resistance (43, 44). Antiviral 294 use was higher in the intervention period, though prescribing rates were low (<5%), likely 295 reflecting the availability of antivirals and the stringent prescribing requirements at the time of 296 the study.

297 One of the major limitations of this study is that due to the real-word, pre-post study design, 298 several epidemiological factors could not be controlled for. The control and intervention 299 periods were very different in terms of the stage of the COVID-19 pandemic. The control 300 period coincided largely with the first wave, which peaked at approximately 10,000 new 301 cases/day in mid-July (45). The intervention period was initiated in November, which was the 302 start of a surge in cases in California, with approximately 47,000 new cases/day at the end 303 of December and >100,000 cases/day in January (45). The study may also have been 304 impacted by seasonality, with higher rates of respiratory infections generally encountered in 305 winter (the intervention period) (46). In addition to environmental factors, COVID-19 306 treatment guidelines or practices were rapidly evolving (47, 48), and the availability of 307 effective treatments changed over time (49), making clinical comparisons challenging. 308 Though the demographics of our patient population were not statistically different between 309 periods, other non-collected characteristics of patients presenting to the ED may have 310 differed (50), particularly as ED volumes were low during the beginning of the pandemic.

311 Nevertheless, this study provides an important insight into the outcomes observed following 312 the implementation of a rapid POC SARS-CoV-2 test at a time when new cases of COVID-313 19 were high. It is also important to note that while our study supports the use of POC PCR 314 tests in an emergency care setting, high-throughput centralized testing for SARS-CoV-2 315 remains an important diagnostic tool for patients not in need of immediate results. In this 316 study, system identifiers were missing from the dataset, so it was not possible to analyze 317 TAT for the cobas 6800 or ePlex systems separately; however, it is recognized that TAT 318 using the ePlex SARS-CoV-2 Test is shorter than the cobas SARS-CoV-2 test. The ability to 319 perform tests on the cobas Liat System, or other POC platforms, may increase capacity for 320 testing to be conducted on centralized systems with broader respiratory pathogen testing 321 panels, potentially improving testing efficiency and antibiotic prescribing practices.

322 Conclusion

- 323 In conclusion, this study confirms that the cobas Liat SARS-CoV-2 & Influenza A/B test
- 324 provides a considerably shorter TAT compared with centralized laboratory PCR methods,
- 325 particularly those using sample batching, in a real-world emergency care setting. Decreased
- 326 TAT also has the potential to reduce ED LOS in some patient populations and allows for
- 327 better patient management and informed treatment decisions, in-line with improved antibiotic
- 328 stewardship.

329 Funding

330 This study was funded by Roche Molecular Systems, Inc.

331

332 Disclosures

- 333 EMR, JAC, and KC are employees of Roche Molecular Systems Inc., and EMR holds
- 334 company stock. LM and NKT have received payment or honoraria for lectures,

- 335 presentations, or advisory boards from Roche Molecular Systems, Inc., and LM has received
- 336 honoraria from Roche Diagnostics Solutions.

337 Acknowledgements

- 338 The authors would like to thank Christopher Dodoo of Roche Molecular Systems, Inc.,
- 339 Pleasanton, California, USA, who contributed statistical support; Jeffrey Flack of University
- of California, Davis, California, USA for support with dataset creation; and Babar Javed of
- 341 Roche Molecular Systems, Inc., Pleasanton, California, USA, who was the study manager.
- 342 Medical writing support was provided by Samantha Forster of Elements Communications Ltd
- 343 (Westerham, UK) and was funded by Roche Molecular Systems, Inc.
- 344 In the US, the cobas SARS-CoV-2 & Influenza A/B test (17) is only for use under the Food
- 345 and Drug Administration's Emergency Use Authorization. COBAS, LIAT, EPLEX and
- 346 GENMARK DX are trademarks of Roche. All other product names and trademarks are the
- 347 property of their respective owners.

349 References

350 351	1.	Centers for Disease Control and Prevention. 2022. COVID data tracker. https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed 09 May 2022.
352 353 354 355 356 357	2.	Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, Derqui- Fernandez N, Barnett JL, Whitfield MG, Varro R, Charlett A, Kundu R, Fenn J, Cutajar J, Quinn V, Conibear E, Barclay W, Freemont PS, Taylor GP, Ahmad S, Zambon M, Ferguson NM, Lalvani A. 2022. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis 22:183–195.
358 359 360 361 362	3.	Elliott P, Haw D, Wang H, Eales O, Walters CE, Ainslie KEC, Atchison C, Fronterre C, Diggle PJ, Page AJ, Trotter AJ, Prosolek SJ, Ashby D, Donnelly CA, Barclay W, Taylor G, Cooke G, Ward H, Darzi A, Riley S. 2021. Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science 374:eabl9551.
363 364 365 366	4.	Baldanti F, Ganguly NK, Wang G, Möckel M, O'Neill LA, Renz H, Dos Santos Ferreira CE, Tateda K, Van Der Pol B. 2022. Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future. Crit Rev Clin Lab Sci doi:10.1080/10408363.2022.2045250:1–15.
367 368 369	5.	Cabinet Office. 2022. Guidance: COVID-19 response: living with COVID-19, <i>on</i> Gov.uk. <u>https://www.gov.uk/government/publications/covid-19-response-living-with-covid-19/covid-19-response-living-with-covid-19</u> . Accessed 26 May 2022.
370 371 372	6.	Centers for Disease Control and Prevention. 2021. Public health recommendations for fully vaccinated people. <u>https://www.cdc.gov/media/releases/2021/p0308-</u> vaccinated-guidelines.html. Accessed 26 May 2022.
373 374	7.	Israel Ministry of Health. 2021. Israel to life all Coronavirus restrictions, <i>on</i> Gov.il. https://www.gov.il/en/departments/news/23052021-02. Accessed 26 May 2022.
375 376 377 378	8.	Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, Cohen C, Fry AM. 2020. Decreased influenza activity during the COVID-19 pandemic - United States, Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly Rep 69:1305-1309.
379 380 381 382	9.	Foley DA, Yeoh DK, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, Le H, Levy A, Moore HC, Blyth CC. 2021. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019–related public health measures. Clinical Infectious Diseases 73:e2829-e2830.
383 384 385	10.	Tanaka H, Ogata T, Shibata T, Nagai H, Takahashi Y, Kinoshita M, Matsubayashi K, Hattori S, Taniguchi C. 2022. Shorter incubation period among COVID-19 cases with the BA.1 Omicron variant. Int J Environ Res Public Health 19:6330.

- Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, Abdel-Moneim
 AS. 2022. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of
 concern and its global perspective. J Med Virol 94:1738-1744.
- Stadler E, Chai KL, Schlub TE, Cromer D, Polizzotto MN, Kent SJ, Skoetz N, Estcourt
 L, McQuilten ZK, Wood EM, Khoury DS, Davenport MP. 2022. Determinants of
 passive antibody effectiveness in SARS-CoV-2 infection. medRxiv
 doi:10.1101/2022.03.21.22272672:2022.03.21.22272672.
- Soltan AAS, Yang J, Pattanshetty R, Novak A, Yang Y, Rohanian O, Beer S, Soltan
 MA, Thickett DR, Fairhead R, Zhu T, Eyre DW, Clifton DA, Collaborative CT. 2022.
 Real-world evaluation of rapid and laboratory-free COVID-19 triage for emergency
 care: external validation and pilot deployment of artificial intelligence driven
 screening. Lancet Digit Health 4:e266-e278.
- Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC. 2020.
 Comparison of the analytical sensitivity of seven commonly used commercial SARS CoV-2 automated molecular assays. J Clin Virol 130:104578.
- 40115.Dancer SJ. 2021. Reducing the risk of COVID-19 transmission in hospitals: focus on402additional infection control strategies. Surgery (Oxford, Oxfordshire) 39:752-758.
- 403 16. El Tawil C, El Hussein M, Souaiby N, Helou M. 2022. Emergency department
 404 management of COVID-19 suspected patients. An international perspective. Int J
 405 Public Health 67:1604534.
- 406 17. Roche Molecular Systems Inc. 2022. Instructions for use: cobas® SARS-CoV-2 &
 407 Influenza A/B Nucleic acid test for use on the cobas® Liat® System. v3.0.
- 40818.GenMark Diagnostics I. 2020. ePlex®SARS-CoV-2 Test assay manual.409https://www.fda.gov/media/136282/download. Accessed 31 May 2022.
- 410 19. Roche Molecular Systems. 2022. Instructions for use: cobas® SARS-CoV-2:
 411 qualitative assay for use on the cobas® 6800/8800 Systems v8.0.
- 412 20. Roche molecular Systems I. 2015. cobas® 6800/8800 Systems: systems
 413 specifications.
- 41421.UC Davis Health News. 2020. UC Davis Health speeds up COVID-19 testing.415https://health.ucdavis.edu/news/headlines/uc-davis-health-speeds-up-covid-19-416testing/2020/04. Accessed 23 Jun 2022.
- 22. Zhen W, Smith E, Manji R, Schron D, Berry GJ. 2020. Clinical evaluation of three
 sample-to-answer platforms for detection of SARS-CoV-2. J Clin Microbiol 58:e0078320.
- 420 23. Roche Diagnostics Limited. 2022. Product information: ePlex® System.
 421 <u>https://diagnostics.roche.com/global/en/products/systems/eplex-system.html</u>.
 422 Accessed 4 August 2022.

- 423 24. SAS Institute Inc. 2013. The SAS®System for Linux, v9.4. Cary, NC, USA.
- 424 25. Centers for Disease Control and Prevention. 2022. Defining adult overweight and
 425 obesity <u>https://www.cdc.gov/obesity/basics/adult-defining.html</u>. Accessed 7 June
 426 2022.
- 427 26. Tsang HF, Leung WMS, Chan LWC, Cho WCS, Wong SCC. 2021. Performance
 428 comparison of the Cobas® Liat® and Cepheid® GeneXpert® systems on SARS-CoV429 2 detection in nasopharyngeal swab and posterior oropharyngeal saliva. Expert Rev
 430 Mol Diagn 21:515–518.
- 431 27. Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, Westblade LF, Jin R,
 432 Love N, Ding K, Garg S, Huang A, Sickler J, Tran NK. 2021. Clinical performance of
 433 the point-of-care cobas Liat for detection of SARS-CoV-2 in 20 minutes: a multicenter
 434 study. J Clin Microbiol 59:e02811-20.
- 435 28. Möckel M, Bolanaki M, Hofmann J, Stein A, Hitzek J, Holert F, Fischer-Rosinský A,
 436 Slagman A. 2022. SARS-CoV-2 screening in patients in need of urgent inpatient
 437 treatment in the Emergency Department (ED) by digitally integrated point-of-care
 438 PCR: a clinical cohort study. Diagn Microbiol Infect Dis 102:115637.
- 439 29. Egilmezer E, Walker GJ, Bakthavathsalam P, Peterson JR, Gooding JJ, Rawlinson W,
 440 Stelzer-Braid S. 2018. Systematic review of the impact of point-of-care testing for
 441 influenza on the outcomes of patients with acute respiratory tract infection. Rev Med
 442 Virol 28:e1995.
- 44330.Jeong HW, Heo JY, Park JS, Kim WJ. 2014. Effect of the influenza virus rapid antigen444test on a physician's decision to prescribe antibiotics and on patient length of stay in445the emergency department. PLoS One 9:e110978-e110978.
- Jun S-H, Kim J-Y, Yoon Y-H, Lim C-S, Ch H-J, Choi S-H. 2016. The effect of the rapid
 antigen test for influenza on clinical practice in the emergency department: a
 comparison of periods before and after the 2009 H1N1 influenza pandemic. Signa
 Vitae 11:74-89.
- 45032.Our World in Data. 2022. Share of SARS-CoV-2 sequences that are the delta variant.451https://ourworldindata.org/coronavirus#coronavirus-country-profiles. Accessed 4 July4522022.
- 453 33. Ohsfeldt RL, Choong CK, Mc Collam PL, Abedtash H, Kelton KA, Burge R. 2021.
 454 Inpatient hospital costs for COVID-19 patients in the United States. Adv Ther
 455 38:5557-5595.
- 456 34. Di Fusco M, Shea KM, Lin J, Nguyen JL, Angulo FJ, Benigno M, Malhotra D, Emir B,
 457 Sung AH, Hammond JL, Stoychev S, Charos A. 2021. Health outcomes and economic
 458 burden of hospitalized COVID-19 patients in the United States. J Med Econ 24:308459 317.
- Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L. 2021. Novel SARS-CoV-2
 variants: the pandemics within the pandemic. Clin Microbiol Infect 27:1109-1117.

- McPadden J, Warner F, Young HP, Hurley NC, Pulk RA, Singh A, Durant TJS, Gong G,
 Desai N, Haimovich A, Taylor RA, Gunel M, Dela Cruz CS, Farhadian SF, Siner J,
 Villanueva M, Churchwell K, Hsiao A, Torre CJ, Jr., Velazquez EJ, Herbst RS, Iwasaki
 A, Ko AI, Mortazavi BJ, Krumholz HM, Schulz WL. 2021. Clinical characteristics and
 outcomes for 7,995 patients with SARS-CoV-2 infection. PLoS One 16:e0243291e0243291.
- Russell FM, Wang A, Ehrman RR, Jacobs J, Croft A, Larsen C. 2021. Risk factors
 associated with hospital admission in COVID-19 patients initially admitted to an
 observation unit. Am J Emerg Med 46:339-343.
- 471 38. Hansen GT, Moore J, Herding E, Gooch T, Hirigoyen D, Hanson K, Deike M. 2018.
 472 Clinical decision making in the emergency department setting using rapid PCR:
 473 results of the CLADE study group. J Clin Virol 102:42-49.
- van Rijn AL, Nijhuis RHT, Bekker V, Groeneveld GH, Wessels E, Feltkamp MCW, Claas
 ECJ. 2018. Clinical implications of rapid ePlex® Respiratory Pathogen Panel testing
 compared to laboratory-developed real-time PCR. Eur J Clin Microbiol Infect Dis
 37:571–577.
- 478 40. Benirschke RC, McElvania E, Thomson RB, Jr., Kaul KL, Das S. 2019. Clinical impact
 479 of rapid point-of-care PCR influenza testing in an urgent care setting: a single-center
 480 study. J Clin Microbiol 57:e01281-18.
- 481 41. Pedersen CJ, Rogan DT, Yang S, Quinn JV. 2018. Using a novel rapid viral test to
 482 improve triage of emergency department patients with acute respiratory illness
 483 during flu season. J Clin Virol 108:72-76.
- 484 42. Langford BJ, So M, Raybardhan S, Leung V, Soucy JR, Westwood D, Daneman N,
 485 MacFadden DR. 2021. Antibiotic prescribing in patients with COVID-19: rapid review
 486 and meta-analysis. Clin Microbiol Infect 27:520-531.
- 487 43. World Health Organization. 2012. The evolving threat of antimicrobial resistance:
 488 options for action, *on* World Health Organization.
 489 https://apps.who.int/iris/handle/10665/44812 Accessed 30 June 2022.
- 49044.File TM, Jr., Srinivasan A, Bartlett JG. 2014. Antimicrobial stewardship: importance491for patient and public health. Clin Infect Dis 59 Suppl 3:S93-S96.
- 492 45. USAFacts. 2022. California coronavirus cases and deaths.
 493 <u>https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/state/california</u>.
 494 Accessed 9 June 2022.
- 49546.Price RHM, Graham C, Ramalingam S. 2019. Association between viral seasonality496and meteorological factors. Sci Rep 9:929-929.
- 497 47. National Institutes of Health. April 29, 2022 2022. COVID-19 treatment guidelines.
 498 <u>https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/guidelines-</u>
 499 <u>development/</u>. Accessed 13 June 2022.

- 48. Lee CK, Merriam LT, Pearson JC, Lipnick MS, McKleroy W, Kim EY. 2022. Treating
 501 COVID-19: Evolving approaches to evidence in a pandemic. Cell Rep Med 3:100533.
- 502 49. Cascella M, Rajnik M, Aleem A, Dulebohn SC, R DN. May 4, 2022 2022. Features,
 503 evaluation, and treatment of coronavirus (COVID-19), *on* StatPearls Publishing.
 504 <u>https://www.ncbi.nlm.nih.gov/books/NBK554776/</u>. Accessed 15 June 2022.
- 505 50. Matsunaga N, Hayakawa K, Asai Y, Tsuzuki S, Terada M, Suzuki S, Ohtsu H, Kitajima
 506 K, Toyoda A, Suzuki K, Suzuki M, Saito S, Uemura Y, Shibata T, Kondo M, Nakamura507 Uchiyama F, Yokota K, Saito F, Izumi K, Sugiura W, Ohmagari N. 2022. Clinical
 508 characteristics of the first three waves of hospitalised patients with COVID-19 in
 509 Japan prior to the widespread use of vaccination: a nationwide observational study.
 510 Lancet Reg Health West Pac 22:100421.

512 Table 1: Patient demographics

	Control period	Intervention period	p-value
	(Centralized PCR)	(POC PCR)	
Total patient visits, n	4339	4540	
Age (years), n (%)			0.63ª
≤30	1152 (26.55%)	1259 (27.73%)	
31–40	492 (11.34%)	505 (11.12%)	
41–50	481 (11.09%)	485 (10.68%)	
51–60	691 (15.93%)	685 (15.09%)	
61–70	723 (16.66%)	727 (16.01%)	
71–80	488 (11.25%)	526 (11.59%)	
≥81	312 (7.19%)	353 (7.78%)	
Age (years)			0.18 ^b
Mean (SD)	47.47 (24.17)	46.76 (25.34)	
Median (IQR)	51 (29, 66)	51 (28, 67)	
Range	(0, 90)	(0, 90)	
BMI ^c (kg/m²), n (%)			0.11 ^a
Below 18.5 (underweight)	236 (5.44%)	270 (5.95%)	
18.5–24.9 (healthy)	767 (17.68%)	711 (15.66%)	
25.0–29.9 (pre-obesity)	756 (17.42%)	680 (14.98%)	
30–39.9 (obesity class I)	726 (16.73%)	736 (16.21%)	
≥40 (obesity class II)	251 (5.78%)	259 (5.70%)	
Unknown ^e	1579 (36.39%)	1850 (40.75%)	
BMI ^c (kg/m²)			0.56 ^b
Mean (SD)	28.47 (8.22)	28.60 (8.59)	
Median (IQR)	27.4 (22.7, 32.8)	27.4 (22.4, 33.5)	
Range	(14.0, 65.1)	(14.0, 65.5)	
Sex, n (%)			0.30 ^{a,d}
Female	2086 (48.08%)	2233 (49.19%)	
Male	2251 (51.88%)	2305 (50.77%)	
Other	2 (0.05%)	2 (0.04%)	
Ethnicity, n (%)			0.24 ^{a,d}
Hispanic/Latino	969 (22.33%)	972 (21.41%)	

Not Hispanic/not Latino	3318 (76.47%)	3534 (77.84%)	
Unknown ^e	50 (1.15%)	34 (0.75%)	-
Not reported	2 (0.05%)	0 (0.00%)	-
Race, n (%)			0.12 ^{a, d}
American Indian/Alaskan	46 (1.06%)	47 (1.04%)	
Native			
Asian	342 (7.88%)	408 (8.99%)	-
Black/African-American	836 (19.27%)	936 (20.62%)	-
Native Hawaiian/Pacific	103 (2.37%)	84 (1.85%)	-
Islander			
White	1843 (42.48%)	1889 (41.61%)	-
Multiple/other	1104 (25.44%)	1133 (24.96%)	
Not reported	65 (1.50%)	43 (0.95%)	

513 This table may include multiple visits per patient. All individuals with symptoms of a possible SARS-

514 CoV-2 infection, and a PCR SARS-CoV-2 test ordered by a clinician during the control period (April

515 2020–October 2020) or the intervention period (December 2020– May 2021), were considered eligible

- 516 for this study and are included in this summary table.
- 517 ^aChi-square test
- 518 ^bStudent's t-test
- 519 °N=58 observations were excluded from the BMI analysis due to data quality issues. BMI cut-off
- 520 based on Centers for Disease Control and Prevention definitions (25)
- 521 ^dChi-square test excludes 'Other', 'Unknown', or 'Not reported' categories
- ⁶Unknown category indicates subjects for whom the corresponding information is not available or
- 523 reported as unknown
- 524 BMI, body mass index; IQR, interquartile range; PCR, polymerase chain reaction; POC, point-of-care;
- 525 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation
- 526

527 Table 2: Summary of SARS-CoV-2 test turnaround time (TAT), order to result

Control period	Intervention period	p-value ^a
(Centralized PCR)	(POC PCR)	
4339	4540	
		<0.0001 ^c
13.32 (6.77)	1.29 (1.79)	
12.3 (7.93, 18.7)	0.98 (0.7, 1.43)	
1.92, 74.38	0.42, 79.92	-
538 (12.40%)	638 (14.05%)	<0.0001
13.5 (7.45)	1.18 (1.04)	
12.26 (7.87, 18.73)	0.93 (0.72, 1.33)	
2.08, 74.38	0.43, 17.07	-
3789 (87.32%)	3902 (85.95%)	<0.0001
13.27 (6.66)	1.31 (1.88)	
12.27 (7.95, 18.65)	0.98 (0.7, 1.45)	
1.92, 61.7	0.42, 79.92	
0 (0.00%)	0 (0.00%)	
12 (0.28%)	0 (0.00%)	N/A
21.01 (5.82)	N/A	
19.73 (15.83, 26.575)	N/A	
14.2, 28.73	N/A	
	Control period (Centralized PCR) 4339 13.32 (6.77) 12.3 (7.93, 18.7) 1.92, 74.38 538 (12.40%) 13.5 (7.45) 12.26 (7.87, 18.73) 2.08, 74.38 3789 (87.32%) 13.27 (6.66) 12.27 (7.95, 18.65) 1.92, 61.7 0 (0.00%) 12 (0.28%) 21.01 (5.82) 19.73 (15.83, 26.575) 14.2, 28.73	Control periodIntervention period(Centralized PCR)(POC PCR)4339454013.32 (6.77)1.29 (1.79)12.3 (7.93, 18.7)0.98 (0.7, 1.43)1.92, 74.380.42, 79.92538 (12.40%)638 (14.05%)13.5 (7.45)1.18 (1.04)12.26 (7.87, 18.73)0.93 (0.72, 1.33)2.08, 74.380.43, 17.073789 (87.32%)3902 (85.95%)13.27 (6.66)1.31 (1.88)12.27 (7.95, 18.65)0.98 (0.7, 1.45)1.92, 61.70.42, 79.920 (0.00%)0 (0.00%)12 (0.28%)0 (0.00%)21.01 (5.82)N/A14.2, 28.73N/A

528 This table may include multiple visits per patient. All individuals with symptoms of a possible SARS-

529 CoV-2 infection, and a PCR SARS-CoV-2 test ordered by a clinician during the control period (April

530 2020–October 2020) or the intervention period (December 2020– May 2021), were considered eligible

531 for this study and are included in this summary table.

532 ^aWilcoxon rank-sum test

533 ^bTAT was calculated as the difference between test order date-time and result date-time

- 535 °Test excludes 'Invalid/other' category
- 536 ^dPCR SARS-CoV-2 test was the cobas SARS-CoV-2 test on the 6800 System or ePlex SARS-CoV-2
- 537 Test during the control period, and was the Liat SARS-CoV-2 & Influenza A/B test during the
- 538 intervention period
- 539 IQR, interquartile range; N/A, not applicable; PCR, polymerase chain reaction; POC, point-of-care;
- 540 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation

541 Table 3: Summary of patient's emergency department (ED) length of stay (LOS)

	Control period	Intervention period	p-value ^a
	(Centralized PCR)	(POC PCR)	
Total patient visits, n	4339	4540	
Patient's ED LOS (hours)			0.02 ^b
Mean (SD)	13.50 (16.49)	13.30 (23.01)	
Median (IQR)	7.15 (4.08, 17.78)	7.56 (4.62, 14.62)	-
Range	0.32, 202.47	0.70, 776.88	-
Missing	0 (0.00%)	0 (0.00%)	-
ED LOS (hours) by PCR SARS-			
CoV-2 test result ^c			
Positive, n (%)	538 (12.40%)	638 (14.05%)	<0.0001
Mean (SD)	12.20 (14.79)	21.57 (37.83)	
Median (IQR)	6.04 (3.10, 15.40)	9.28 (4.60, 25.97)	-
Range	0.53, 106.88	0.98, 383.27	-
Missing	0 (0.00%)	0 (0.00%)	-
Negative, n (%)	3789 (87.32%)	3902 (85.95%)	0.76
Mean (SD)	13.67 (16.69)	11.95 (19.22)	
Median (IQR)	7.32 (4.20, 18.10)	7.38 (4.63, 13.57)	-
Range	0.32, 202.47	0.70, 776.88	-
Missing	0 (0.00%)	0 (0.00%)	-
Invalid/other, n (%)	12 (0.28%)	0 (0.00%)	N/A
Mean (SD)	17.37 (22.17)	N/A	
Median (IQR)	7.25 (2.85, 29.58)	N/A	-
Range	1.15, 75.72	N/A	-
Missing	0 (0.00%)	0 (0.00%)	
ED LOS (hours) by ED patient			
visit disposition ^{c,d}			
Discharge, n (%)	2139 (49.30%)	2258 (49.74%)	<0.0001
Mean (SD)	7.36 (11.69)	8.20 (21.30)	
Median (IQR)	4.43 (2.67, 7.12)	5.10 (3.35, 7.62)	1
Range	0.32, 196.22	0.70, 776.88	1
Hospital admission, n (%)	1576 (36.32%)	1740 (38.33%)	<0.0001

Mean (SD)	22.80 (19.07)	20.10 (24.03)	
Median (IQR)	18.48 (8.74, 30.49)	13.50 (8.43, 25.37)	
Range	1.53, 202.47	1.23, 383.27	
ICU admission, n (%)	617 (14.22%)	535 (11.78%)	0.19
Mean (SD)	11.09 (12.30)	12.83 (21.00)	
Median (IQR)	7.45 (5.02, 12.33)	7.87 (5.50, 13.38)	
Range	1.23, 178.15	1.38, 346.48	
Death, n (%)	7 (0.16%)	6 (0.13%)	1
Mean (SD)	8.65 (6.15)	7.11 (2.88)	
Median (IQR)	7.80 (3.92, 10.83)	6.51 (4.62, 9.27)	
Range	3.57, 21.32	4.12, 11.65	

542 This table may include multiple visits per patient. All individuals with symptoms of a possible SARS-

543 CoV-2 infection, and a PCR SARS-CoV-2 test ordered by a clinician during the control period (April

544 2020–October 2020) or the intervention period (December 2020– May 2021), were considered eligible

- 545 for this study and are included in this summary table.
- 546 ^aWilcoxon rank-sum test
- 547 ^bTest excludes 'Invalid/other' category
- 548 °PCR SARS-CoV-2 test was the cobas SARS-CoV-2 test on the 6800 System or the ePlex SARS-

549 CoV-2 Test during the control period, and was the Liat SARS-CoV-2 & Influenza A/B test during the

- 550 intervention period
- ^dThere were no data in the control period and only one record in the intervention period for 'Other'

disposition category. ED LOS summary statistics for 'Other' disposition category were therefore not

- 553 calculated
- 554 ICU, intensive care unit; IQR, interquartile range; N/A, not applicable; PCR, polymerase chain
- reaction; POC, point-of-care; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD,
- 556 standard deviation

557 Table 4: Summary of emergency department (ED) disposition

	Control period	Intervention period	p-value ^a
	(Centralized PCR)	(POC PCR)	
Total nationt visits n	(0011112001 01()	4540	
Total patient visits, if	4000	4540	0.01 ^b
ED disposition, n (%)			0.01
Discharge	2139 (49.30%)	2258 (49.74%)	0.72
Hospital admission	1576 (36.32%)	1741 (38.35%)	0.1
ICU admission	617 (14.22%)	535 (11.78%)	0.0026
Death	7 (0.16%)	6 (0.13%)	0.72
Other	0 (0.00%)	1 (0.02%)	N/A
ED disposition by PCR SARS-			
CoV-2 test result ^c , n, (%)			
Positive	538 (12.40%)	638 (14.05%)	0.0005
Discharge	302 (56.13%)	285 (44.67%)	0.0002
Hospital admission	236 (43.87%)	352 (55.17%)	0.0002
ICU admission	69 (12.83%)	85 (13.32%)	0.8
Death	0 (0.00%)	1 (0.16%)	N/A
Other	0 (0.00%)	0 (0.00%)	-
Negative	3789 (87.32%)	3902 (85.95%)	0.0029
Discharge	1830 (48.30%)	1973 (50.56%)	0.09
Hospital admission	1952 (51.52%)	1923 (49.28%)	0.54
ICU admission	547 (14.44%)	450 (11.53%)	0.0006
Death	7 (0.18%)	5 (0.13%)	0.54
Other	0 (0.00%)	1 (0.03%)	N/A
Inconclusive	12 (0.28%)	0 (0.00%)	N/A
Discharge	7 (58.33%)	0 (0.00%)	N/A
Hospital admission	5 (41.67%)	0 (0.00%)	N/A
ICU admission	1 (8.33%)	0 (0.00%)	N/A
Death	0 (0.00%)	0 (0.00%)	-
Other	0 (0.00%)	0 (0.00%)	-

558 This table may include multiple visits per patient. All individuals with symptoms of a possible SARS-

559 CoV-2 infection, and a PCR SARS-CoV-2 test ordered by a clinician during the control period (April

- 560 2020–October 2020) or the intervention period (December 2020– May 2021), were considered eligible
- 561 for this study and are included in this summary table.
- ^aChi-square test. Subgroup p-values were adjusted for multiplicity using the false discovery rate
- 563 method
- 564 ^bTest excludes 'Other' disposition category
- 565 °PCR SARS-CoV-2 test was the cobas SARS-CoV-2 test on the 6800 System or the ePlex SARS-
- 566 CoV-2 Test during the control period, and was the Liat SARS-CoV-2 & Influenza A/B test during the
- 567 intervention period
- 568 ICU, intensive care unit; N/A, not applicable; PCR, polymerase chain reaction; POC, point-of-care;
- 569 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

571 Table 5: Summary of anti-infective prescriptions

	Control period	Intervention period	p-value ^a
	(Centralized PCR)	(POC PCR)	
Total patient visits, n	4339	4540	
Anti-infective prescription n, (%)			<0.0001
Antibiotic only	1933 (44.55%)	1730 (38.11%)	<0.0001
Antiviral only	38 (0.94%)	131 (3.13%)	<0.0001
Antibiotic and antiviral	200 (4.61%)	216 (4.76%)	0.74
No antibiotic or antiviral	2168 (49.97%)	2463 (54.25%)	<0.0001
Anti-infective prescription by test			
result [⊳] , n, (%)			
Positive	538 (12.40%)	638 (14.05%)	<0.0001
Antibiotic only	158 (29.37%)	99 (15.52%)	<0.0001
Antiviral only	20 (3.72%)	95 (14.89%)	<0.0001
Antibiotic and antiviral	83 (15.43%)	129 (20.22%)	0.04
No antibiotic or antiviral	277 (51.49%)	315 (49.37%)	0.47
Negative	3789 (87.32%)	3902 (85.95%)	<0.0001
Antibiotic only	1771 (46.74%)	1631 (41.80%)	<0.0001
Antiviral only	18 (0.48%)	36 (0.92%)	0.02
Antibiotic and antiviral	117 (3.09%)	87 (2.23%)	0.02
No antibiotic or antiviral	1883 (49.70%)	2148 (55.05%)	<0.0001
Invalid/other	12 (0.28%)	0 (0.00%)	N/A
Antibiotic only	4 (33.33%)	0 (0.00%)	N/A
Antiviral only	0 (0.00%)	0 (0.00%)	-
Antibiotic and antiviral	0 (0.00%)	0 (0.00%)	-
No antibiotic or antiviral	8 (66.67%)	0 (%)	N/A
Anti-infective prescription by ED			
disposition ^{c,d} , n, (%)			
Discharge	2139 (49.30%)	2258 (49.74%)	0.0004
Antibiotic only	437 (20.43%)	388 (17.18%)	0.02
Antiviral only	6 (0.28%)	19 (0.84%)	0.02
Antibiotic and antiviral	7 (0.33%)	1 (0.04%)	0.03
No antibiotic or antiviral	1689 (78.96%)	1850 (81.93%)	0.02

Hospital admission	1576 (36.32%)	1740 (38.33%)	<0.0001
Antibiotic only	1025 (65.04%)	970 (55.75%)	<0.0001
Antiviral only	27 (1.71%)	101 (5.80%)	<0.0001
Antibiotic and antiviral	126 (7.99%)	155 (8.91%)	0.35
No antibiotic or antiviral	398 (25.25%)	514 (29.54%)	0.01
ICU admission	617 (14.22%)	535 (11.78%)	0.02
Antibiotic only	467 (75.69%)	369 (68.97%)	0.03
Antiviral only	5 (0.81%)	11 (2.06%)	0.1
Antibiotic and antiviral	67 (10.86%)	60 (11.21%)	0.85
No antibiotic or antiviral	78 (12.64%)	95 (17.76%)	0.03
Death	7 (0.16%)	6 (0.13%)	0.8
Antibiotic only	4 (57.14%)	3 (50.00%)	0.8
Antiviral only	0 (0.00%)	0 (0.00%)	-
Antibiotic and antiviral	0 (0.00%)	0 (0.00%)	-
No antibiotic or antiviral	3 (42.86%)	3 (50.00%)	0.8

572 One patient may receive multiple anti-infective prescriptions per visit. Antibiotic or antiviral

573 prescriptions are counted as one instance per visit. All individuals with symptoms of a possible SARS-

574 CoV-2 infection, and a PCR SARS-CoV-2 test ordered by a clinician during the control period (April

575 2020–October 2020) or the intervention period (December 2020– May 2021), were considered eligible

576 for this study and are included in this summary table.

^aChi-square test. Subgroup p-values were adjusted for multiplicity using the false discovery rate

578 method

^bPCR SARS-CoV-2 test was the cobas SARS-CoV-2 test on the 6800 System or the ePlex SARS-

580 CoV-2 Test during the control period, and was the Liat SARS-CoV-2 & Influenza A/B test during the

- 581 intervention period
- 582 ^cThere were no data in the control period and only one record in the intervention period for 'Other'
- 583 disposition category. ED LOS summary statistics for 'Other' disposition category were therefore not
- 584 calculated

- 585 ED, emergency department; ICU, intensive care unit; N/A, not applicable; PCR, polymerase chain
- reaction; POC, point-of-care; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

